Triple primary synchronous liver cancer in one patient: the first case report and origin speculation through bioinformatics Authors: Zheng Zhou, Shuai Hu, Ting Liu, Danling He, Ting Bu, Lingqiu Mao, Xiyan Zheng, Maoyun Xie, Xianjie Shi Published: 2026 ABSTRACT AbstractIntroductionA diagnosis of multiple primary liver tumors is extremely rare. Preoperative diagnosis based on imaging findings is difficult. Moreover, the clinical benefits of treatment strategies for multiple liver cancers remain unclear. Here, we report a case of three synchronous primary liver tumors with three distinct pathological types—hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined hepatocellular-cholangiocarcinoma (cHCC‑CCA)—in a single patient. Bioinformatics analysis supported at least two clonal origins, with cHCC‑CCA and ICC sharing a common lineage based on identical HBV integration sites.Case presentationA 63-year-old female with a history of hepatitis B for several years presented with three lesions in hepatic segment VIII. Multiphase magnetic resonance imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid revealed a diagnosis of multiple lesions, namely, cHCC‑CCA, with multiple intrahepatic metastases. The AFP level was normal, while the CA 19 − 9 level was mildly elevated (normal range ≤ 30.00 U/ml). Hepatectomy was performed, and postoperative assessment confirmed that the large lesion was cHCC‑CCA. However, the small lesions close to the large lesion were HCC and ICC. Gene testing revealed distinct mutational profiles among the three tumors. Similar gene mutations were detected in cHCC‑CCA and ICC. We also found that gene fragments of hepatitis B virus-C (HBV-C) were inserted into the genomes of ICC and cHCC‑CCA rather than that of HCC. The genomic integration site of HBV-C in cHCC‑CCA and ICC was the same.ConclusionWe report an extremely rare case of three synchronous primary liver tumors with three distinct pathological types (HCC, ICC, and cHCC‑CCA) in a single patient. Bioinformatics analysis supported at least two clonal origins, with cHCC‑CCA and ICC sharing a common lineage based on identical HBV integration sites. Hepatectomy represents a potential radical strategy for the treatment of multiple PLCs.Keywords: Hepatocellular carcinoma, Intrahepatic cholangiocarcinoma, Combined hepatocellular–cholangiocarcinoma, Multiple primary liver cancer, Hepatectomy, Case report Introduction Primary liver cancer (PLC) is the most common malignant liver tumor and the fifth leading cause of cancer-related death worldwide. The occurrence of synchronous multiple liver cancers comprising different primary hepatic tumors is very low. The preoperative diagnosis of multiple liver tumors is always difficult because of the lack of specific imaging features. Simultaneous double primary liver cancer, including HCC and ICC, has been reported in a range of case reports [1]. However, more than two liver malignancies occurred simultaneously in one patient, which was not previously reported. Here, we report an extremely rare case of triple synchronous primary liver cancer—comprising combined hepatocellular-cholangiocarcinoma (cHCC‑CCA), hepatocellular carcinoma (HCC), and intrahepatic cholangiocarcinoma (ICC)—in a patient who underwent radical liver resection. To our knowledge, no similar case with three distinct pathological types confirmed by histology has been previously reported. Case presentation The patient was a 63-year-old woman who had been diagnosed with chronic hepatitis B infection several years prior. She had never received antiviral therapy. Magnetic resonance imaging (MRI) revealed abnormal clumping of the signal shadow in hepatic segment VIII, measuring 5.4 × 4.1 × 4.9 cm with a relatively clear boundary. Low signal intensity was observed on T1-weighted imaging (T1WI), and uneven high signal intensity was observed on T2-weighted imaging (T2WI). Multiphase enhancement using gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid showed early enhancement of uneven edges in the arterial phase and filling enhancement in the portal vein phase. The delayed phase showed partial clearance of the lesion with a relatively low enhancement area. In the hepatobiliary stage at 10 min and 20 min, the mass was scattered in small flakes with slightly increased signal intensity shadowing. The distal right hepatic vein (RHV) and distal portal vein (RPV) were invaded (Fig. 1A). A small lesion in hepatic segment VII/VIII, measuring 1 cm, had imaging features that were similar to those of the hepatobiliary phase (Fig. 1B). Hepatic segment VII, close to the inferior vena cava (IVC), showed a lesion with low signal intensity (Fig. 1C). The interval between preoperative MRI and surgical resection was 6 days. Imaging, pathology, and macroscopic features of triple primary synchronous liver cancer. A Multiphase enhancement using Gd-EOB-DTPA shows early enhancement of uneven edges in the arterial phase (arrow). B The hepatic segment VII/VIII lesion shows contrast clearance in the venous phase. C Segment VII beside the IVC shows a lesion with enhancement in the arterial phase (arrow). D The dominant tumor nodule (approximately 5.5 cm) in segment VIII is cHCC‑CCA. Unequivocal cholangiocytic (arrow 80%) and hepatocytic areas (star 20%) of cell differentiation are shown (hematoxylin and eosin staining ×40). E The segment VII/VIII lesion is considered to be an ICC of moderate differentiation (×100). F The segment VII lesion beside the IVC was diagnosed as HCC, pT1a, with moderate differentiation (×100). G The lesion of segment VIII was diagnosed as cHCC‑CCA, the VII/VIII lesion was ICC, and the segment VIII lesion close to the IVC was diagnosed as HCC. Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid; IVC, inferior vena cava; cHCC‑CCA, combined hepatocellular-cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; HCC, hepatocellular carcinoma. The immunohistochemical profiles of the three tumors are summarized in (Table 2) The radiologist considered the diagnosis to be multiple cHCC‑CCAs with distal RHV and RPV invasion, and no distant metastasis or lymph node metastasis was found on the multiphase contrast-enhanced computed tomography (CT) scan. The AFP level was normal, and the carbohydrate antigen (CA) 19 − 9 level was mildly elevated at 72.30 U/ml (normal range ≤ 30.00 U/ml). The hepatitis B virus (HBV) deoxyribonucleic acid (DNA) test was negative. The above laboratory examination and imaging results were consistent with the diagnosis of cHCC‑CCA. Preoperative liver function was defined as a Child‒Pugh score of A (bilirubin concentration, 8.69 µmol/L; albumin concentration, 39.63 g/L; alanine aminotransferase concentration, 12.9 U/L; aspartate aminotransferase concentration, 22.19 U/L; prothrombin time, 13.2 s; platelet count, 178 × 109/L). Ultrasonic elastography revealed a value of 8.8 kPa, indicating liver fibrosis (F2–F3). Segment VIII hepatectomy plus resection of the two smaller lesions was planned, and the estimated future liver remnant (FLR) was 67.7%. Consequently, resection of hepatic segment VIII and part of hepatic segment VII was performed (Fig. 1G). Intraoperative ultrasound was used to examine the remaining liver lesions. No intrahepatic metastasis or swollen lymph nodes were observed. The Pringle method was used for hepatectomy. The hilar hepatis was blocked once for 5 min, blood loss was less than 50 ml, and no blood transfusion was needed. The hepatic segment VIII tumor was resected separately from the small lesion in hepatic segment VII, which was close to the IVC. The resected liver specimen measured 9 × 8 × 4 cm, containing two tumor nodules: a dominant nodule of 5.5 × 5 × 3.5 cm and a smaller nodule of 1 × 0.8 × 0.7 cm. Postoperative pathological results revealed that the dominant tumor nodule (approximately 5.5 cm in greatest dimension) in hepatic segment VIII was cHCC‑CCA with vascular invasion (Fig. 1D). The proportion of intrahepatic carcinoma was 80%, while that of HCC was small, accounting for 20%. The differentiation was moderate, vascular tumor invasion was found, and there was no nerve invasion. The final diagnosis was cHCC‑CCA, pT3, and moderate differentiation. The hepatic segment VII/VIII lesion was diagnosed as an ICC (Fig. 1E). The TNM stage was pT1aN0M0 IA. The distance between the nodules was 2 cm. The hepatic segment VII lesion close to the IVC was diagnosed as HCC (Fig. 1F) with pT1a, moderate differentiation, Edmondson-Steiner level II, and no microvascular invasion or satellite nodules. The resection margin was negative (R0). Next‑generation sequencing (NGS) revealed that the three liver tumors were triple primary liver cancers characterized by different mutations in genes, among which the cHCC‑CCA and ICC were relatively similar. The relatively similar mutated genes indicated biological homologous characteristics between the cHCC‑CCA and ICC (Table 1). Multiple chimeric reads were detected in the breakpoints of the human genome at chr5: 106,350,971 and the HBV genome at HBV-C: 2976. Bioinformatics analysis revealed that the gene fragments of hepatitis B virus-C (HBV-C) were inserted into the genomes of ICC and cHCC‑CCA but not in that of HCC. The integration site of HBV in cHCC‑CCA and ICC was the same (Fig. 2). Table 1List of gene alterations and proportion of viral reads among total sample reads. cHCC‑CCA, combined hepatocellular-cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; HBV-C, hepatitis B virus-CGenec.changep.changeVariant allele frequency (%)cHCC‑CCA ( S8, large)ICC (S7/8, small)HCC (S8, paracaval)Shared mutations (cHCC‑CCA and ICC)* MKI67c.6934G > Tp.A2312S15.494.060 CHD4c.5402G > Ap.R1801Q13.873.26‡0 KDRc.3694 C > Tp.R1232W12.381.95‡0 GRIN2Ac.2303G > Tp.G768V15.432.86‡0 PALLDc.2047_2058delp.D683_R686del10.471.3‡0HCC-unique mutations * TP53c.715 A > Gp.N239D008.41 STAT3c.1032G > Tp.Q344H005.07 EPHA5c.2531_2532delinsATp.W844Y008.46Other BRAFc.1406G > Cp.G469A13.3800 TERTamplification2.32.14.2 Proportion of HBV-C reads(%)--0.0341930.016430.056967†*Rows under this heading indicate shared mutations between cHCC‑CCA and ICC (first group) or HCC-unique mutations (second group). Clonality assessment relies primarily on the same HBV integration site†The low number of HBV reads in HCC (0.056967%) was not supported by any chimeric reads and therefore likely represents background noise or nonintegrated viral DNA rather than true integration‡The lower VAFs in ICC (e.g., 1.3%–4.06%) may reflect differences in tumor purity, subclonal mutations, or technical variability. Clonality assessment in this study primarily relied on the identical HBV integration site rather than low-VAF mutations List of gene alterations and proportion of viral reads among total sample reads. cHCC‑CCA, combined hepatocellular-cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; HBV-C, hepatitis B virus-C *Rows under this heading indicate shared mutations between cHCC‑CCA and ICC (first group) or HCC-unique mutations (second group). Clonality assessment relies primarily on the same HBV integration site †The low number of HBV reads in HCC (0.056967%) was not supported by any chimeric reads and therefore likely represents background noise or nonintegrated viral DNA rather than true integration ‡The lower VAFs in ICC (e.g., 1.3%–4.06%) may reflect differences in tumor purity, subclonal mutations, or technical variability. Clonality assessment in this study primarily relied on the identical HBV integration site rather than low-VAF mutations Visualizations of HBV-C genome integration into the human genome for tumor tissues at the breakpoints of HBV-C:2976 and chr5:106350971. A: Integrative Genomics Viewer visualization of HBV-C genome integration into the human genome detected from ICC tissue. B: Integrative Genomics Viewer visualization of HBV-C genome integration into the human genome detected from tumor tissue in cHCC‑CCA tissue. C: Integrative Genomics Viewer visualization of the breakpoint of chr5:106350971 in the human genome detected from HCC tissue; no chimeric read was found. HBV-C, hepatitis B virus-C; cHCC‑CCA, combined hepatocellular-cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; HCC, hepatocellular carcinoma. Chimeric reads are sequencing reads that contain both human and viral DNA sequences, indicating a viral integration event. The absence of chimeric reads in panel C (HCC) indicates no detectable HBV integration event, distinguishing it from cHCC‑CCA and ICC The patient recovered well without biliary fistula or liver failure. She was discharged 2 weeks after surgery. The patient was regularly followed up after surgery. As of the last follow-up in March 2026, the patient had been followed for 42 months. At 8 months postoperative, intrahepatic recurrence was detected, and ultrasound-guided microwave ablation was performed. Postablation pathology confirmed the presence of hepatocellular carcinoma. Since the ablation, the patient has been regularly followed up every 3–6 months with contrast-enhanced CT and detection of tumor markers (AFP and CA19-9) and has shown no evidence of further recurrence or metastasis. The patient is currently alive and in good general condition. The patient was negative for HBV-DNA preoperatively, and postoperative repeated testing has remained negative. In accordance with the 2024 WHO hepatitis B guidelines, antiviral therapy is not recommended for inactive HBsAg carriers with persistently negative HBV DNA and normal ALT levels and therefore was not administered. Her liver function has remained stable, with no signs of hepatitis activity. After the initial surgery, all three tumors were at early pathological stages (cHCC‑CCA pT3, ICC pT1a, and HCC pT1a) with negative surgical margins. The multidisciplinary team discussed the potential benefits and risks of adjuvant therapy with the patient and family, who declined postoperative adjuvant chemotherapy or radiotherapy and opted for close surveillance. When intrahepatic recurrence (HCC) occurred at 8 months, the patient again declined systemic therapy and underwent microwave ablation, with no new lesions detected during subsequent follow-up. Methods All pathological diagnoses were made according to the 2019 WHO Classification of Tumors of the Digestive System (5th edition). Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded sections as part of the routine diagnostic workup. The following antibodies were used: Hepatocyte, CK7, CK19, CK8/18, CD34, Ki-67, Glypican-3, GS, CD10, CD117, CD56, HBcAg, and HBsAg. The staining results were evaluated independently by two experienced hepatopathologists, and all diagnoses were confirmed by consensus. Genomic DNA was extracted from fresh frozen tumor tissues. Next-generation sequencing was performed on an Illumina NovaSeq 6000 platform with 150-bp paired-end reads. A custom panel targeting 605 cancer-related genes (full exonic regions) was used, covering approximately 2.1 Mb of the human genome, with additional probes specifically designed to capture the full-length HBV genome. The mean sequencing depth exceeded 800× for all three tumor samples. Somatic variants were called using Mutect2 and filtered with a minimum allele frequency threshold of 2% and a minimum of five supporting variant reads. Only variants annotated as pathogenic or likely pathogenic in ClinVar or COSMIC were retained. Tumor purity was estimated by histopathological review. HBV integration sites were identified using BreakDancer and Delly, after which the chimeric reads were manually reviewed using Integrative Genomics Viewer (IGV). To support the rarity of this case, we performed a systematic search of PubMed and Web of Science from database inception to December 2025. Search terms included: synchronous, concurrent, multiple, multifocal, hepatocellular carcinoma, HCC, intrahepatic cholangiocarcinoma, ICC, combined hepatocellular-cholangiocarcinoma, cHCC‑CCA, combined hepatocellular and cholangiocarcinoma, and case report. No previous report of three synchronous primary liver cancers with distinct histologies (HCC, ICC, and cHCC‑CCA) was identified. Results The three tumors showed distinct immunohistochemical profiles, which is consistent with their respective diagnoses. The complete IHC results are summarized in (Table 2). According to the pathology report, in some areas the tumor cells were arranged in a trabecular or cord‑like pattern with infiltrative growth, marked nuclear atypia, frequent mitotic figures, and abundant granular eosinophilic cytoplasm — features consistent with hepatocytic differentiation. In other areas, the cells grew in a glandular or cord‑like pattern with enlarged, hyperchromatic nuclei, prominent nucleoli, and eosinophilic cytoplasm — features consistent with cholangiocytic differentiation. Immunohistochemically, the cholangiocytic component (~ 80%) was positive for CK7 with focal CK19 positivity, while the hepatocytic component (~ 20%) showed partial hepatocyte positivity. CD34 staining revealed focal microvascular staining, and the Ki‑67 index was approximately 20%. The ICC lesion (small nodule in segment VIII) was positive for CK7 and CK19 (partial) and negative for hepatocytes, with CD34 staining limited to peritumoral vessels and a Ki-67 index of approximately 40%. These features, according to the 2019 WHO classification, are consistent with intrahepatic cholangiocarcinoma. The HCC lesion (paracaval nodule in segment VIII) was diffusely positive for hepatocytes and negative for CK7/CK19, with diffuse microvascular CD34 staining and a Ki-67 index of approximately 15%, confirming well-differentiated hepatocellular carcinoma. All three tumors were negative for Glypican-3, CD117, CD56, and HBcAg. HBsAg positivity was observed only in adjacent nontumor liver tissue. Table 2Immunohistochemical profiles of the three tumorsAntibodycHCC‑CCA (S8, large)ICC (S8, small)HCC (S8, paracaval)HepatocytePartial +–+CK7++–CK19Focal +Partial +–CK8/18+++CD34Focal microvascularPeritumoral vessels+Diffuse microvascularKi-67~ 20%~ 40%~ 15%Glypican-3–––GSPartial +Scattered ++CD10Focal +––CD117–––CD56–––HBcAg–––HBsAg (tumor itself)–––HBsAg (adjacent liver)+++ Immunohistochemical profiles of the three tumors Discussion The classification of cHCC‑CCA has changed and has been challenged by authors since the first case of cHCC‑CCA was described in 1903 by Capt. Goodman [2], who discriminated three types of cHCC‑CCA: I, collision tumors, including HCC and ICC within the same liver; II, transitional tumors that transition from HCC differentiation to ICC differentiation; and III, fibrolamellar tumors representing a special type of HCC tumor. The incidence of cHCC‑CCA is relatively low and was redefined by the World Health Organization (WHO) classification in 2019 as a primary liver carcinoma exhibiting both HCC and ICC differentiation [3]. The incidence of cHCC‑CCA in primary liver cancer reported in the current literature is 0.5–0.54% [4, 5]. The origin of cHCC‑CCA remains controversial. The progenitor cells of tumors that exhibit both biliary and hepatocytic differentiation play important roles in the origin of cHCC‑CCA [6]. However, some studies have shown that cHCC‑CCA transforms from mature hepatocytes into malignant cells [7]. Gene sequencing has indicated that the genetics of cHCC‑CCA are similar to those of HCC [8]. Conversely, the genetic testing of this patient indicated that the genes were similar between the ICC and cHCC‑CCA, indicating that the two types of tumors most likely had the same origin. In our case, we speculate that the ICC component comprised 80% of the cHCC‑CCA mass, which may explain the genetic similarity between the ICC and cHCC‑CCA. Double primary hepatic cancer was first described in 1989 [9]. The reported incidence of double liver cancer is 0.25% for PLC [1]. The typical imaging features of HCC are early enhancement in the arterial phase and washout of the contrast medium in the late phase. ICC was diagnosed on the basis of peripheral enhancement in the early and late phases. According to some studies, the characteristics of cHCC‑CCA are more similar to those of HCC than those of ICC, with 30.2% of patients presenting with an enhancement pattern resembling that of ICC on CT and 58.1% of patients presenting with imaging features that are indicative of HCC [10, 11]. Gigante’s research revealed a sensitivity of 48% and a specificity of 81% for lesions with a mixed pattern in cHCC‑CCA, including progressive enhancement and arterial enhancement with washout [12]. Preoperative diagnosis of multiple liver cancers is difficult. In a retrospective study of 35 patients with double liver cancer, only one patient was diagnosed preoperatively with features of double hepatic cancer (both HCC and ICC) on CT imaging [1]. In the present case, early preoperative imaging was unable to discriminate the different types of tumors. The mass in segment VIII was considered cHCC‑CCA because it was consistent with some features of ICC and HCC. Both the small lesion in segment VII and the lesion in segment VIII close to the IVC were difficult to diagnose because of a lack of special imaging features. The image similarity may be attributed to the gene homology between cHCC‑CCA and ICC. The close relationship between hepatitis B virus (HBV) infection and hepatocellular carcinoma (HCC) is widely recognized. The HBV X protein encoded by HBV DNA plays an important role in the molecular mechanism of HCC pathogenesis [13]. TERT promoter mutations are the most common genetic alterations, accounting for 60% of these cases [14]. These mutations act as recurrent insertion sites for HBV genomes. Extensive epidemiological data have shown that hepatitis B surface antigen (HBsAg)-positive patients have a significantly increased risk of intrahepatic cholangiocarcinoma (ICC). Compared with those who test negative for both HBsAg and hepatitis C, these patients have an approximate odds ratio of 4.5. However, no sufficient epidemiological evidence can support the association between specific HBV genotypes and ICC. In relation to the development of combined hepatocellular-cholangiocarcinoma (cHCC‑CCA), whether the presence of HBV is a classic risk factor for HCC or ICC remains unknown. The HBV-related risk in patients with cHCC‑CCA falls between that seen in HCC, where the HBV prevalence is higher, and that of ICC, where the HBV prevalence is lower [15]. Specifically, 80–100% of patients with double primary liver cancer are reported to have a concurrent HBV infection [1, 16]. However, in our study, the results of genetic tests revealed that gene fragments of HBV-C were inserted into the genomes of ICC and cHCC‑CCA rather than in that of HCC. An identical HBV-C integration site (chr5:106350971) was detected in both cHCC‑CCA and ICC but not in HCC. This finding suggests a possible clonal relationship; however, it is not definitive without orthogonal validation. The integration site is located in an intergenic region, and its functional significance remains unknown. To our knowledge, this specific breakpoint has not been previously reported as a recurrent HBV integration hotspot. HBV integration events can recur at specific genomic hotspots, and the possibility of independent but coincidental integration cannot be entirely excluded. The observed differences in viral read proportions across lesions may reflect technical variability, differences in tumor purity, or sampling heterogeneity. Orthogonal validation (e.g., locus-specific PCR) was not performed because of the limited residual tissue. The three tumors exhibited three distinct histological types, which was determined by the clinical diagnosis. Genomic evidence, particularly the identical HBV‑C integration site (chr5:106350971) detected in both cHCC‑CCA and ICC, along with partially overlapping mutations (e.g., MKI67, CHD4, and KDR), suggests that cHCC‑CCA and ICC may have originated from a single HBV‑infected progenitor cell clone that underwent divergent phenotypic differentiation. In contrast, the HCC lesion lacked this integration event and harbored distinct mutations (e.g., TP53, STAT3, and EPHA5), which may represent an independent clonal origin. Therefore, while the patient presented with three pathological types, the molecular data were consistent with at least two distinct clonal lineages. Thus, the tumors represent three distinct pathological entities, but molecular findings suggest at least two clonal origins (cHCC‑CCA and ICC sharing a common lineage, while HCC is independent). Notably, these findings are suggestive but not conclusive, and pathological diagnosis remains the basis for clinical management. The frequency of simultaneous increases in AFP and CA 19 − 9 is greater for cHCC‑CCA than for pure HCC or ICC, and increases in both AFP and CA19-9 are critical for the diagnosis of double liver cancer [1]. However, the normal serum AFP level and slightly increased CA 19 − 9 level in the present case did not support the preoperative diagnosis of double liver cancer. It has been suggested that radical treatment in the form of liver resection is the treatment of choice for patients with triple primary liver cancer [17]. In our patient, hepatectomy, including that of segment VIII and part of segment VII, was performed after the preoperative evaluation. A negative margin of at least 1 cm in resection distance is an independent risk factor for HCC recurrence. Since lymph node metastasis is common in ICC, liver resection and lymph node biopsy and dissection are the standard treatments. Several studies have shown that the clinical characteristics and lymph node metastasis of cHCC‑CCA are similar to those of ICC [18]. Radical resection and regional lymph node dissection are as important for ICC as they are for cHCC‑CCA [17]. In our case, no lymph node metastasis was detected on preoperative imaging or intraoperative exploration. Prophylactic dissection of lymph nodes remains controversial. Pathological evidence supported the diagnosis of triple primary liver cancer. Systemic therapy should have been the preferred treatment for this patient because of the preoperative diagnosis of cHCC‑CCA with multiple intrahepatic metastases, and the patient would have lost the chance to undergo radical resection because the postoperative pathological stage was early for each tumor. Therefore, we should consider the possibility of PLC for patients with multiple liver tumors. Previous studies have reported that the prognosis of cHCC‑CCA is intermediate between that of HCC and ICC [18, 19]. Yoon’s study reported that the 1-, 3-, 5-, and 10-year tumor recurrence rates for double primary liver cancer were 60.8%, 71.8%, 80.7%, and 80.7%, respectively. Another study reported 1-, 3-, 5-, and 10-year overall survival (OS) rates for double primary liver cancer of 73.3%, 35.6%, 30.5%, and 11.1%, respectively [20]. The postresection prognosis for double primary liver cancer is more dependent on the tumor stage of the ICC component than that of the HCC component [16]. ICC may play a more important role than HCC in influencing the prognosis of multiple liver cancers. Multivariate analysis in one retrospective study revealed that tumor size and histological differentiation of the ICC component were independent risk factors for OS in patients with double primary liver cancer [1]. However, the prognosis of patients with multiple primary liver cancers is still uncertain because of the lack of clinical studies. In the present case, the patient was followed for 42 months. Although intrahepatic recurrence (HCC) occurred at 8 months postsurgery, it was successfully managed with microwave ablation. The patient has since remained recurrence-free and is currently alive with good performance status. These long-term outcomes suggest that despite the complexity of the three distinct pathological types presented in a single patient, aggressive surgical resection combined with timely management of recurrent lesions can achieve favorable survival. This case highlights two important clinical points. First, multiple liver lesions in patients with chronic liver disease should not be automatically interpreted as intrahepatic metastases; pathological confirmation of each lesion may reveal distinct primary tumors with different therapeutic implications. Second, accurate histopathological and molecular diagnosis is crucial for guiding treatment decisions. In this case, despite the presence of multiple tumors, surgical resection was feasible and achieved favorable long-term outcome, supporting a potential role for aggressive surgical management in selected patients with multiple primary liver cancers. After a full discussion of risks and benefits, the patient’s decision to decline adjuvant systemic therapy further highlights the importance of shared decision-making in such rare and complex clinical scenarios. In clinical practice, reliable preoperative differentiation between multiple primary liver cancers and intrahepatic metastases remains extremely difficult. However, certain features may raise suspicion for multiple primaries: (1) lesions located in different liver segments; (2) absence of definite vascular invasion or satellite nodules around each lesion on imaging; (3) different imaging enhancement patterns or morphological characteristics among lesions. When these features are present and the lesions are technically resectable, a thorough evaluation is warranted to assess the potential benefits of surgical resection. These observations, while derived from a single case, suggest that the threshold for considering curative resection in patients with multiple liver lesions should not be set too high based on imaging alone. Limitations Owing to the retrospective nature of the case and limited sample availability, matched normal tissue was not available for germline filtering. Formal clonality or phylogenetic analysis was not performed. The absence of matched normal tissue precludes definitive germline filtering, and the lack of formal phylogenetic or clonal inference analysis limits the certainty of clonal assignment. Additionally, variability in variant allele frequencies across lesions may reflect subclonal heterogeneity or sampling bias rather than definitive clonal relationships. Therefore, the interpretation of shared mutations and inferred clonal origins should be considered preliminary and hypothesis-generating. Nonetheless, the observation of partially overlapping mutations and identical HBV integration sites is suggestive of a possible common origin but not definitive. The pathological diagnosis remains the basis for clinical management. Conclusion We report an extremely rare case of three synchronous primary liver tumors with three distinct pathological types (HCC, ICC, and cHCC‑CCA) in a single patient. Bioinformatics analysis supported at least two clonal origins, with cHCC‑CCA and ICC sharing a common lineage based on identical HBV integration sites. Hepatectomy remains a potential radical strategy for such complex presentations. Acknowledgments None Financial support All the authors have no financial support statements to make. Abbreviations Primary liver cancer Hepatocellular carcinoma Intrahepatic cholangiocarcinoma Combined hepatocellular-cholangiocarcinoma Alpha-fetoprotein Carbohydrate antigen 19 − 9 Magnetic resonance imaging T1-weighted imaging T2-weighted imaging Right hepatic vein Distal portal vein Inferior vena cava Computed tomography Hepatitis B virus Hepatitis B virus-C Deoxyribonucleic acid Future liver remnant Next‑generation sequencing Hepatitis B surface antigen Overall survival Authors' contributions Study concept and design (ZZ), acquisition of data (SH, TL), analysis and interpretation of data (LM, XZ), drafting of the manuscript (DH, TB), technical support (MX), and study supervision (XS). All the authors have made significant contributions to this study and have approved the final manuscript. Funding This work was supported by the following funding sources: Funding Agency: Shenzhen Science and Technology Project. • Grant Number: JCYJ20230807110911025. Funding Agency: Shenzhen Basic Research Project (Natural Science Foundation). • Grant Number: JCYJ20240813150607010. Funding Agency: The Eighth Affiliated Hospital of Sun Yat-sen University. • Grant Number: BKXM0042. Data availability The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request. Owing to privacy and ethical restrictions related to patient-derived genomic data, raw sequencing files cannot be made publicly available in an open repository. However, deidentified mutation profiles and HBV integration site information are included within the article and supplementary materials (if applicable). Further inquiries can be directed to the corresponding author (Dr. Xianjie Shi; email: [shixianjie301@126.com](mailto: shixianjie301@126.com) ). Declarations Ethics approval and consent to participate The patient provided informed consent, and the study design was approved by the appropriate ethics review board. This study was approved by the ethics committee. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Zheng Zhou, Shuai Hu and Ting Liu contributed equally to this work. Contributor Information Maoyun Xie, Email: sz6619@126.com. Xianjie Shi, Email: shixianjie301@126.com. References Associated Data Data Availability Statement The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request. Owing to privacy and ethical restrictions related to patient-derived genomic data, raw sequencing files cannot be made publicly available in an open repository. However, deidentified mutation profiles and HBV integration site information are included within the article and supplementary materials (if applicable). Further inquiries can be directed to the corresponding author (Dr. Xianjie Shi; email: [shixianjie301@126.com](mailto: shixianjie301@126.com) ).